Vaccine composition for transpulmonary or transnasal administration

JP7863350B2Active Publication Date: 2026-05-21NAGASAKI UNIVERSITY
View PDF 6 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
NAGASAKI UNIVERSITY
Filing Date
2022-03-25
Publication Date
2026-05-21

AI Technical Summary

Technical Problem

Current mRNA vaccines are formulated for intramuscular administration and primarily induce systemic immunity, struggling to effectively induce local immunity in the lungs where COVID-19 infection and replication occur, leading to concerns about vaccine effectiveness in preventing infection.

Method used

A transpulmonary or transnasal vaccine composition comprising a nucleic acid-containing carrier coated with γ-polyglutamic acid, incorporating a cationic molecule and CpG oligodeoxyribonucleotide as an adjuvant, with a specific charge ratio and molecular weight range, to deliver mRNA encoding the spike protein of SARS coronavirus-2, enhancing local and systemic immunity.

Benefits of technology

The composition effectively induces both cellular and humoral immunity in the lungs and throughout the body, providing stable delivery and storage of nucleic acids, and can be administered without freezing, addressing the limitations of conventional mRNA vaccines.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007863350000002
    Figure 0007863350000002
  • Figure 0007863350000003
    Figure 0007863350000003
  • Figure 0007863350000004
    Figure 0007863350000004
Patent Text Reader

Abstract

A vaccine composition for transpulmonary or transnasal administration contains a nucleic-acid-containing carrier having such a structure that a complex comprising a nucleic acid encoding an antigen protein and a cationic molecule is coated with γ-polyglutamic acid or a salt thereof. In the vaccine composition for transpulmonary or transnasal administration, the charge ratio among the nucleic acid, the cationic molecule, and the γ-polyglutamic acid or the salt thereof may be 1:(2 to 8 inclusive):(4 to 16 inclusive). The cationic molecule may be 1,2-dioleoyl-3-trimethylammoniumpropane.
Need to check novelty before this filing date? Find Prior Art